| ALT | Alternative lengthening of telomeres |
| AML | Acute myeloid leukemia |
| APL | Acute promyelocytic leukemia |
| AR | Androgen receptor |
| CRC | Colorectal cancer |
| DCs | Dendritic cells |
| DDR | DNA damage response |
| DSBs | Double strand breaks |
| EBV | Epstein-Barr virus |
| EC | Endometrial cancer |
| ER | Estrogen receptor |
| EMT | Epithelial to mesenchymal transition |
| GBM | Glioblastoma |
| GC | Gastric cancer |
| HCC | Hepatocellular carcinoma |
| HDAC | Histone deacetylase |
| HNC | Head and neck cancer |
| KO | Knock out |
| MM | Multiple myeloma |
| MI | Momordin Ic |
| NBs | Nuclear bodies |
| NPC | Nuclear pore complex |
| NSCLC | Non-small-cell lung cancer |
| OGD | Oxygen and glucose deprivation |
| OSCC | Oral squamous cell carcinoma |
| PCa | Prostate cancer |
| PTM | Post-translational modification |
| ROS | Reactive oxygen species |
| SIM | SUMO interacting motif |
| TNBC | Triple-negative breast cancer |
| UBLs | Ubiquitin-like modifiers |